Newsroom
Newsroom
Blog Posts
Today’s blog will focus on Narcan, a critical opioid overdose rescue drug that is produced from thebaine, Antheia’s first commercial-scale, biomanufactured pharmaceutical ingredient. Read on...
Blog Posts
Ben’s work enables teams across the business to track and make sense of more than a decade of R&D data....
Blog Posts
The years-long journey medicines take from the farm to the pharmacy is a delicate one, vulnerable to extreme weather, mechanical failures, logistical and shipping delays,...
Blog Posts
Antheia was a proud sponsor of this year’s SynBioBeta, the Global Synthetic Biology Conference hosted annually in the San Francisco Bay Area....
Blog Posts
Pavel and his team have developed the processes to accurately measure the quantity of our biosynthetic KSMs and APIs produced via biomanufacturing, which is no...
Blog Posts
In early May, U.S. Secretary of State Antony J. Blinken visited Antheia, HQ in Menlo Park, California for a tour of our labs and a...
Industry News
Antheia, a Menlo Park, California-based pharmaceutical ingredient maker, raised $56 million in Series C funding....
Industry News
Pharmaceutical ingredient manufacturer Antheia raised $56 million led by Global Health Investment Corp. at an undisclosed valuation. Cofounder and CEO Christina Smolke told Forbes she...
Industry News
Antheia, a biomanufacturer that makes a key ingredient for the opioid overdose treatment Narcan, reeled in $56 million in a series C financing....
Industry News
Menlo Park–based biomanufacturing company Antheia, founded in 2015 by Dr. Christina Smolke and Dr. Kristy Hawkins, announced a $56 million Series C funding round led...
Industry News
Antheia has raised $56 million in a Series C financing round to accelerate its synthetic biology platform, which harnesses engineered yeast to produce essential pharmaceutical...
Industry News
Menlo Park-based Narcan ingredient maker Antheia raised $56 million in Series C funding....
Industry News
Antheia, a biomanufacturer that makes a key ingredient for the opioid overdose treatment Narcan, reeled in $56 million in a series C financing....
Industry News
Menlo Park–based biomanufacturing company Antheia, founded in 2015 by Dr. Christina Smolke and Dr. Kristy Hawkins, announced a $56 million Series C funding round led...
Industry News
Antheia has raised $56 million in a Series C financing round to accelerate its synthetic biology platform, which harnesses engineered yeast to produce essential pharmaceutical...
Industry News
Menlo Park-based Narcan ingredient maker Antheia raised $56 million in Series C funding....
Industry News
Antheia, a Menlo Park, CA-based pharmaceutical ingredient manufacturer, raised $56M in Series C funding....
Industry News
Antheia, manufacturer of a major Narcan ingredient, raised a $56 million Series C round, co-founder and CEO, Christina Smolke, tells Axios....
Press Releases
Antheia and Olon established this partnership in 2022 to leverage Olon’s fermentation sites across Italy. Olon has since played a pivotal role as a CDMO...
Press Releases
Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMS and APIs...
Press Releases
Company's first full-scale fermentation run reinforces commercial viability for a robust pipeline of Biosynthetic KSMS and APIs...
Press Releases
Antheia, the pharmaceutical ingredient manufacturer transforming supply chains, today announced the appointment of John Nicols to Chair its Board of Directors. Nicols joins co-founders Dr....
Press Releases
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank,...
Blog Posts
Today’s blog will focus on Narcan, a critical opioid overdose rescue drug that is produced from thebaine, Antheia’s first commercial-scale, biomanufactured pharmaceutical ingredient. Read on...
Blog Posts
Ben’s work enables teams across the business to track and make sense of more than a decade of R&D data....
Blog Posts
The years-long journey medicines take from the farm to the pharmacy is a delicate one, vulnerable to extreme weather, mechanical failures, logistical and shipping delays,...
Blog Posts
Antheia was a proud sponsor of this year’s SynBioBeta, the Global Synthetic Biology Conference hosted annually in the San Francisco Bay Area....
Blog Posts
Pavel and his team have developed the processes to accurately measure the quantity of our biosynthetic KSMs and APIs produced via biomanufacturing, which is no...
Blog Posts
In early May, U.S. Secretary of State Antony J. Blinken visited Antheia, HQ in Menlo Park, California for a tour of our labs and a...